MoonLake Immunotherapeutics — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; financial statements are unaudited. MoonLake is a clinical-stage, single-asset biotechnology company developing sonelokimab (SLK), with no approved products and no product-sales revenue.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Revenue | No product-sales revenue | No product-sales revenue |
| Research and development expense | $13.0 million | $7.4 million; up 75.5% |
| General and administrative expense | $6.8 million | $5.5 million; up 23.4% |
| Total operating expenses / operating loss | $19.8 million | $12.9 million; up 53.3% |
| Other income, net | $5.9 million | $0.7 million |
| Net loss | $14.0 million | $12.2 million; loss increased 14.4% |
| Net loss per Class A share, basic and diluted | $0.22 | $0.23 |
| Net cash used in operating activities | $14.9 million | $9.0 million |
| Cash and cash equivalents | $458.4 million | $451.2 million at Dec. 31, 2023 |
| Short-term marketable debt securities | $88.6 million | $59.8 million at Dec. 31, 2023 |
Operating margins are not meaningful because the company has no product revenue. Other income rose primarily because of higher interest income on cash and investments. The filing reports no borrowings; total liabilities were $11.7 million, including $3.7 million of operating lease liabilities. Current assets exceeded current liabilities by $544.7 million.
Cash, cash equivalents and short-term marketable securities totaled approximately $547.1 million at quarter-end. Management believes this funding will cover operating expenses and capital expenditures through the end of 2026, based on its current operating plan. Cash-flow totals included $28.8 million used in investing activities, largely reflecting purchases of short-term securities, and $51.0 million provided by financing activities, primarily from the ATM share issuance.
Material changes and notable items
- R&D expense increased $5.6 million, primarily from clinical-trial preparation for Phase 3 HS studies, clinical supply and logistics, and personnel costs.
- G&A expense increased $1.3 million, reflecting organizational growth, advisory and personnel costs, additional office space and market research; lower share-based compensation partly offset the increases.
- MoonLake sold 914,828 Class A shares through its ATM program for approximately $52.5 million in net proceeds at a weighted-average price of $58.31. Class A shares outstanding rose to 62,874,637 at March 31, 2024.
- The company contributed $150 million to MoonLake AG’s capital reserves in March and incurred $1.6 million of stamp duty. This was an intra-group capital contribution, not operating expense.
- Committed CRO, CMO and other purchase obligations were $61.3 million; total purchase and lease commitments were $65.2 million. The purchase obligations include $8.4 million already recorded as prepaid expenses.
- Potential additional SLK license milestones of up to €299.6 million (reported as $323.4 million at the quarter-end exchange rate) remain contingent on specified regulatory and commercial events. Royalties under the relevant agreements are in the low-to-mid teens as a percentage of net sales.
Outlook, commentary and risks
- Management expected to begin Phase 3 HS trials in Q2 2024, following positive Phase 2b results and supportive FDA and EMA discussions. It expected FDA and EMA end-of-Phase 2 interactions for PsA in mid-2024 and Phase 3 PsA trials in the second half of 2024.
- The company also planned a Phase 3 juvenile HS trial and Phase 2 trials in palmoplantar pustulosis and axial spondyloarthritis, with starts expected in the second half of 2024. These are forward-looking plans, not reported outcomes.
- Management expects significant expenses and operating losses for at least the next three years, with clinical-development costs expected to rise as Phase 3 trials begin. It may need additional funding to commercialize SLK and continue operations; no committed external funding source is identified.
- Key risks include clinical-trial outcomes and timing, regulatory approval, reliance on a single product candidate and third-party manufacturers, access to future financing, intellectual-property matters, and the ability to recruit and retain staff. The company noted reliance on a small number of manufacturers.
- The filing reported no material legal proceedings, no material changes to the risk factors in the prior Form 10-K, and effective disclosure controls at March 31, 2024.
Investor facts to verify
- Whether planned HS, PsA, juvenile HS, PPP and axSpA trials started on the stated timelines, and whether subsequent clinical results support development plans.
- Whether the stated cash runway through the end of 2026 remains supported as trial activity and spending increase.
- How R&D expense, operating cash use and share issuance evolve, including further use of the ATM program.
- The timing and potential cash impact of the €299.6 million of contingent license milestones, royalties and the $61.3 million of purchase commitments.
- Whether manufacturing capacity, regulatory requirements or trial delays create additional funding needs.